SCHEMBL763022

SCHEMBL763022

C=CC(=O)NCCOC(C)OCCNC(=O)C=C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47
TSHR P16473 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TGM2 P21980 5/20 0.35
GAA P10253 1/20 0.35
KDM5B Q9UGL1 1/20 0.34
EPHX2 P34913 1/20 0.33
ITK Q08881 3/20 0.33
BTK Q06187 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21505428 0.92 ZDHHC20 (0.41) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL1994080 0.89 ZDHHC20 (0.53) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL2608232 0.89 ZDHHC20 (0.47) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL1278058 0.87 ZDHHC20 (0.46) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL14337595 0.84 TSHR (0.48) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL14582983 0.84 ZDHHC20 (0.47) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
Acrylamide SCHEMBL29070619 0.81 ZDHHC20 (0.41) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL9888646 0.81 ZDHHC20 (0.41) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL2608182 0.81 ZDHHC20 (0.47) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1
SCHEMBL22840975 0.80 TSHR (0.50) ZDHHC20ZDHHC2TSHRALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192494-A2 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-10-05 WO claimed
WO-2023192494-A2 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-10-05 WO disclosed
US-8137700-B2 Main chain acid-degradable polymers for the delivery of bioactive materials U.S. DEPARTMENT OF ENERGY (US) 2012-03-20 US disclosed
US-20090220615-A1 Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090220615-A1 Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials CTSA, GAA, CTSB ZDHHC20 3182/4885ZDHHC2 2313/4885TSHR 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.